



**ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

**Press Release**

**EssexBio and Tasly to co-develop recombinant protein drugs  
under Strategic Co-Operation Framework Agreement**

\*\*\*

On 28 August 2015, Zhuhai Essex Bio-Pharmaceutical Company Limited (“Zhuhai Essex Bio-Pharmaceutical”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (stock code 1061.hk), entered into a strategic co-operation framework agreement with Tasly Pharmaceutical Group Co., Ltd. (“Tasly”).

Given the complementary relationship between Tasly’s strengths in the research and development and manufacturing of drugs in genetically engineered mammal expression system and Zhuhai Essex Bio-Pharmaceutical’s strengths in the research and development and manufacturing of drugs in genetically engineered microorganism expression system, both parties, after friendly negotiation, agreed to establish a win-win strategic partnership on a complementary, mutually beneficial and co-development basis to commence cooperation on the development and operation of recombinant protein drugs. Pursuant to the Framework Agreement, Zhuhai Essex Bio-Pharmaceutical and Tasly will collaborate in the research and development, clinical tests, manufacturing, sales and marketing of recombinant protein drugs. The co-operation is valid for a period of 10 years from the date of the signing of the Framework Agreement.

According to the information of Tasly, Tasly is the core enterprise of Tasly Holding Group and the representative company of modern Chinese medicine. Tasly was listed in Shanghai Stock Market in August 2002 (SH. 600535). Its core product compound Danshen dropping pill is the first traditional Chinese medicine which entered into Phase III US FDA trials as drugs. The company is the largest dropping pill medical preparation manufacturer in China. Tasly has also established rich R&D pipeline in biological drugs. The company has successfully launched one innovative biological drug with several innovative biological drugs and biosimilar drugs in different R&D stages. Tasly has established the biggest mammal animal genetic engineering expression system product line using continuous perfusion technology in Shanghai.

- End -

**About Essex Bio-Technology Limited:**

Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Group also engaged in the research and development of bFGF products for new indications, as well as other ophthalmic pharmaceutical projects.

*For more information, please contact:*

**Essex Bio-Technology Limited**

Email : [essex@essexbio.com](mailto:essex@essexbio.com)

Tel : (852) 2587-7838

Fax : (852) 2587-7363